Expand DNLI Menu
DNLI MENU

DNLI Stock Posts


Unusual Option Volume

DNLI Denali Therapeutics20.19-2.28 (-10.2%)

Denali Therapeutics trades 2,354 contracts. The company has the following event: on Apr 5, 2026.
View Details...
Unusual Option Volume

DNLI Denali Therapeutics21.85+0.88 (+4.2%)

Denali Therapeutics trades 2,640 contracts. The company has the following event: on Mar 25, 2026. News: Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
View Details...
DNLI #DenaliTherapeutics stock declines -9.5% in after hours trading. See the latest news.

After Hours Decliner

DNLI Denali Therapeutics19.66-0.03-0.2%

After Hours:17.80-1.86 (-9.5%)

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Globe NewswireTue, 9-Dec 4:01 PM
DNLI #DenaliTherapeutics stock declines -9.7% in after hours trading. See the latest news.

After Hours Decliner

DNLI Denali Therapeutics19.66-0.03-0.2%

After Hours:17.75-1.91 (-9.7%)

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Globe NewswireTue, 9-Dec 4:01 PM
DNLI #DenaliTherapeutics stock declines -7.2% in after hours trading. See the latest news.

After Hours Decliner

DNLI Denali Therapeutics19.82-1.44-6.8%

After Hours:18.40-1.42 (-7.2%)

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Globe NewswireMon, 6-Jan 4:30 PM
DNLI #DenaliTherapeutics stock declines -8.9% in after hours trading. See the latest news.

After Hours Decliner

DNLI Denali Therapeutics19.82-1.44-6.8%

After Hours:18.05-1.77 (-8.9%)

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Globe NewswireMon, 6-Jan 4:30 PM
Load Earlier Posts
Market Data Delayed 15 Minutes